DanielA.WeiserMDFAAP

Pediatric Solid Tumor Oncology

Medical Director, Abdominal Solid Tumor Program

Dr. Weiser is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3415 Bainbridge Ave
Bronx, NY 10467
Phone+1 718-741-2342

Fax+1 718-920-6506

Dr. Daniel Weiser is a pediatric hematologist/oncologist in New York City and is affiliated with multiple hospitals in the area, including Children's Hospital at Montefiore (Montefiore Medical Center) and White Plains Hospital. He received his medical degree from Stony Brook University School of Medicine and graduate medical education at NewYork-Presbyterian/Columbia University (Pediatrics) and the Children's Hospital of Philadelphia/University of Pennsylvania (Pediatric Hematology/Oncology). Dr. Weiser has been in practice for over 20 years. He specializes in pediatric solid tumor oncology and is experienced in managing the most complex of patients with Wilms tumor, neuroblastoma, germ cell tumors, hepatoblastoma, and other rare and difficult to treat malignancies..

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2008 - 2011
New York Presbyterian Hospital (Columbia Campus)Residency, Pediatrics, 2004 - 2007
Stony Brook University Health Sciences Center School of MedicineClass of 2004
Haverford CollegeB.S., Neurobiology, 1995 - 1999

Audrey Evans Award for Top Clinical Research, Advances in Neuroblastoma Research 2012
Brigid Leventhal Special Merit Award for Top Pediatric Abstract ASCO, 2011
Arnold P. Gold Foundation Circle of Excellence Columbia University, 2007
Excellence in Humanism and Teaching Award Children's Hospital of New York-Presbyterian, 2005
Fellow American Academy of Pediatrics, 2004
Gold Humanism Honor Society, Inductee 2003
Join now to see all

Neuroblastoma Maintenance Therapy Trial Start of enrollment: 2016 Feb 01
Recruiting
Phase 2

PubMed

Journal Articles

Characterizing primary refractory neuroblastoma: Prediction of outcome by microscopic image analysis
Niazi, K, Weiser DA, Pawel B, Gurcan M, Proc SPIE, Medical Imaging, Digital Pathology, 1/19/2015
Adrenocortical carcinoma with extension to the inferior cava and right atrium: Report in a 20-month-old girl with a TP53 mutation
Levin TL, Berdon WE, Weiser DA, Ribeiro RC, Rad Case Reports, 1/1/2015

Books/Book Chapters

Netter's Pediatrics.
Chapter: White Blood Cell Disorders.
Page 314 - 320Weiser DEditors: T. Florin and S. Ludwig.Elsevier Saunders, Philadelphia, PA2011

Abstracts/Posters

Limited intra-tumor versus inter-tumor heterogeneity as assessed by automated image analysis and proteomic profiling of high-risk neuroblastoma.
Castellanos R, Chung J, Niazi K, Fremed M, Martinez D, Pawel B, Gurcan M, Weiser DA, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 1/18/2015
Defining the biology of primary refractory neuroblastoma.
Weiser D, Albert Einstein Cancer Center Annual Retreat, 1/1/2014
Frequency and clinical significance of ALK aberrations in patients with neuroblastoma.
Weiser D, Children's Oncology Group (COG) Semi-annual Meeting, 1/1/2012

Lectures

Circulating tumor material in osteosarcoma.
Albert Einstein College of Medicine - 1/1/2015
Personalized medicine in pediatrics: the neuroblastoma paradigm.
Norwalk Hospital, CT - 1/1/2015
Precision diagnostics in pediatric disease: neuroblastoma as an example.
Children's Hospital at Montefiore - 1/1/2014
Reaching new heights in neuroblastoma treatment.
1/1/2014
Defining the patients with neuroblastoma who will benefit from ALK inhibition therapy
1/1/2013
ALK-based therapeutic stratification of children with neuroblastoma.
1/1/2012
Stratification of patients with neuroblastoma for targeted ALK therapy.
Children's Hospital of Philadelphia - 1/1/2011
Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.
1/1/2011
Join now to see all